DART Registry: Diagnosing Adverse Drug Reactions Registry
DART Registry: Diagnosing Adverse Drug Reactions Registry
This multicenter Registry is to assess whether the use of pharmacogenomic data results in a meaningful change in a subject's drug or dose regimen. In addition, the Registry will evaluate the relationship between adverse drug reactions (ADR) and genotype and assess resource utilization (emergency department visits and hospitalizations) associated with ADR.
Inclusion Criteria:
Exclusion Criteria:
Subjects may be eligible within 60 days from the date of pharmacogenomic testing.